Congress Stumbles Through Two Science Policy Hearings

WASHINGTON--The National Science Foundation can't see what's on the horizon in science. The federal government doesn't know what the supercollider will ultimately cost. And nobody has a clue how to balance competing demands for scarce science dollars. On February 20, Congress learned those things and more as it took a five-hour stab at setting science policy. The occasion was back-to-back hearings on the president's proposed science budget for 1992, involving first a portion, and then the whol

Written byJeffrey Mervis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

On February 20, Congress learned those things and more as it took a five-hour stab at setting science policy. The occasion was back-to-back hearings on the president's proposed science budget for 1992, involving first a portion, and then the whole, of the House Science, Space, and Technology Committee.

It's not easy for legislators to dissect how the government proposes to spend the $13 billion that has been requested for basic research, much less the $75 billion on research and development across all agencies. So for the past eight years the House science committee has invited the president's science adviser to present his views on the subject and to field questions from the panel. For the past two years that task has fallen to Allan Bromley, a former Yale physicist. He's a favorite of the committee; in fact, new committee chairman Rep. George Brown (D-Calif.) told members that Bromley's written testimony ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies